Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?

International Journal of Radiation Oncology Biology Physics

Volumn 94, Issue 2, 2016, Pages 272-279

  Kountouri, Melpomeni ^a   Zilli, Thomas ^a   Rouzaud, Michel ^a   Dubouloz, Angèle ^a   Linero, Dolors ^b   Escudé, Lluís ^b   Jorcano, Sandra ^b   Miralbell, Raymond ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Radiation Oncology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; GRADING; MULTIVARIANT ANALYSIS; PATIENT MONITORING; RADIOTHERAPY; TOXICITY; UROLOGY;

COMMON TERMINOLOGY CRITERIA; GENITOURINARY TOXICITIES; INTENSITY-MODULATED RADIATION THERAPY; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; OVERALL TREATMENT TIME; PATIENT REPOSITIONING; PROGRESSION FREE SURVIVAL;

PATIENT TREATMENT;

CHOLINE C 11; FLUORINE 18;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS VERSION 3 GRADING SCALE; DISEASE ASSESSMENT; DISTANT METASTASIS FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TOXICITY FREE SURVIVAL; GENITOURINARY TOXICITY; GENITOURINARY TOXICITY FREE SURVIVAL; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PATIENT POSITIONING; PATIENT REPOSITIONING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; RADIATION INJURY; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SEMINAL VESICLE; SEPSIS; TOXICITY; ADVERSE EFFECTS; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DYSURIA; HEMATURIA; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DOSE HYPOFRACTIONATION; DYSURIA; FOLLOW-UP STUDIES; HEMATURIA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84953439824     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.10.055     Document Type: Article

References (38)

1. A. Pollack, G.K. Zagars, G. Starkschall, and et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
2. D.P. Dearnaley, M.R. Sydes, J.D. Graham, and et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
3. A. Al-Mamgani, W.L. van Putten, W.D. Heemsbergen, and et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 980 988
4. W.D. Heemsbergen, A. Al-Mamgani, A. Slot, and et al. Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival Radiother Oncol 110 2014 104 109
5. D.P. Dearnaley, G. Jovic, I. Syndikus, and et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial Lancet Oncol 15 2014 464 473
6. D.A. Kuban, S.L. Tucker, L. Dong, and et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
7. A.L. Zietman, K. Bae, J.D. Slater, and et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from proton radiation oncology group/american college of radiology 95-09 J Clin Oncol 28 2010 1106 1111
8. J.M. Michalski, K. Bae, M. Roach, and et al. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study Int J Radiat Oncol Biol Phys 76 2010 14 22
9. G.A. Viani, E.J. Stefano, and S.L. Afonso Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials Int J Radiat Oncol Biol Phys 74 2009 1405 1418
10. A. Harsolia, C. Vargas, D. Yan, and et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: Dose-volume analysis of a phase II dose-escalation study Int J Radiat Oncol Biol Phys 69 2007 1100 1109
11. A. Ballare, M. Di Salvo, G. Loi, and et al. Conformal radiotherapy of clinically localized prostate cancer: Analysis of rectal and urinary toxicity and correlation with dose-volume parameters Tumori 95 2009 160 168
12. S.T. Peeters, W.D. Heemsbergen, P.C. Koper, and et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
13. R. Miralbell, S.A. Roberts, E. Zubizarreta, and et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: Alpha/beta = 1.4 (0.9-2.2) Gy Int J Radiat Oncol Biol Phys 82 2012 e17 24
14. A. Dasu, and I. Toma-Dasu Prostate alpha/beta revisited - an analysis of clinical results from 14 168 patients Acta Oncol 51 2012 963 974
15. S. Arcangeli, L. Strigari, S. Gomellini, and et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer Int J Radiat Oncol Biol Phys 84 2012 1172 1178
16. A. Pollack, G. Walker, E.M. Horwitz, and et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer J Clin Oncol 31 2013 3860 3868
17. B.F. Koontz, A. Bossi, C. Cozzarini, and et al. A systematic review of hypofractionation for primary management of prostate cancer Eur Urol 68 2015 683 691
18. F. Leborgne, J. Fowler, J.H. Leborgne, and et al. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer Int J Radiat Oncol Biol Phys 82 2012 1200 1207
19. T.N. Eade, A.L. Hanlon, E.M. Horwitz, and et al. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 68 2007 682 689
20. M. Roach 3rd, C. Marquez, H.S. Yuo, and et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 28 1994 33 37
21. T. Zilli, S. Jorcano, M. Rouzaud, and et al. Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: Toxicity and outcome from a dose escalation pilot study Int J Radiat Oncol Biol Phys 81 2011 382 389
22. J.M. Michalski, H. Gay, A. Jackson, and et al. Radiation dose-volume effects in radiation-induced rectal injury Int J Radiat Oncol Biol Phys 76 2010 S123 129
23. A.L. Zietman Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate Jama 299 2008 898 899
24. C. Ares, Y. Popowski, S. Pampallona, and et al. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: A sequential dose-escalation pilot study Int J Radiat Oncol Biol Phys 75 2009 656 663
25. P.J. Hoskin, K. Motohashi, P. Bownes, and et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial Radiother Oncol 84 2007 114 120
26. D.J. Demanes, R.R. Rodriguez, L. Schour, and et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results Int J Radiat Oncol Biol Phys 61 2005 1306 1316
27. P.A. Kupelian, T.R. Willoughby, C.A. Reddy, and et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
28. V. Fonteyne, G. Soete, S. Arcangeli, and et al. Hypofractionated high-dose radiation therapy for prostate cancer: Long-term results of a multi-institutional phase II trial Int J Radiat Oncol Biol Phys 84 2012 e483 490
29. P.P. Lai, M.V. Pilepich, J.M. Krall, and et al. The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: The radiation therapy oncology group 75-06 and 77-06 experience Int J Radiat Oncol Biol Phys 21 1991 925 933
30. C.A. Perez, J. Michalski, D. Mansur, and et al. Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate Cancer J 10 2004 349 356
31. D.J. D'Ambrosio, T. Li, E.M. Horwitz, and et al. Does treatment duration affect outcome after radiotherapy for prostate cancer? Int J Radiat Oncol Biol Phys 72 2008 1402 1407
32. M. Gao, N.A. Mayr, Z. Huang, and et al. When tumor repopulation starts? The onset time of prostate cancer during radiation therapy Acta Oncol 49 2010 1269 1275
33. L.N. Chen, S. Suy, S. Uhm, and et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience Radiat Oncol 8 2013 58
34. J.K. Kang, C.K. Cho, C.W. Choi, and et al. Image-guided stereotactic body radiation therapy for localized prostate cancer Tumori 97 2011 43 48
35. A.J. Katz, M. Santoro, F. Diblasio, and et al. Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years Radiat Oncol 8 2013 118
36. C.R. King, D. Freeman, I. Kaplan, and et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials Radiother Oncol 109 2013 217 221
37. A. Loblaw, P. Cheung, L. D'Alimonte, and et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes Radiother Oncol 107 2013 153 158
38. C.R. King, S. Collins, D. Fuller, and et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: Results from a multi-institutional consortium of prospective trials Int J Radiat Oncol Biol Phys 87 2013 939 945